Earnings Summary

Alnylam Pharmaceuticals, Inc.’s revenue jumped 107% since last year same period to $659.83Mn in the Q2 2024. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated 33.48% jump in its revenue since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit jumped 93.88% since last year same period to $-16.89Mn in the Q2 2024. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated 74.39% jump in its net profits since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit margin jumped 97.04% since last year same period to -2.56% in the Q2 2024. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated 80.81% jump in its net profit margins since last 3-months.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.97 - a 10.19% jump from last quarter’s estimates.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.97.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) jumped 94.12% since last year same period to -0.13 in the Q2 2024. This indicates that the Alnylam Pharmaceuticals, Inc. has generated 94.12% annual rate of jump in its earning per share (EPS) in the last 4 quarters.